CorVel
CRVL Nasdaq· Health Care Services
Last close · Oct 26, 2026
$84.59
KIRA · Stoqly’s AI analyst, in plain words
- CorVel had $959M of revenue in fiscal 2026, up 7.0% on the year before. Over five years, revenue changed +11.6% a year on average.
- CorVel made $110M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 17.5% a year.
- Free cash flow was $110M in fiscal 2026, 11.5% of revenue.
- CorVel returned $56.2M to shareholders in fiscal 2026, 51% of free cash flow. The diluted share count fell 0.7%.
Market cap
$4.3B
P/E
37.6x
Revenue
$959M
Net income
$110M
Free cash flow
$110M
Operating margin
—
CorVel in 30 seconds · fiscal 2026
Are sales growing?
+7.0%
Yes. Sales grew 7.0% last year.
Does it make a profit?
11.5%
Yes. It keeps 11.5% of every sale as profit.
Does profit turn into cash?
11.5%
Yes. 11.5% of sales ends up as free cash.
How is the share priced?
37.6x
One share costs 37.6 times its yearly profit per share. Typical for its sector: 27.9x.
What CorVel does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K · May 22, 2026
- Legal name
- CORVEL CORPORATION
- CIK
- 0000874866
CorVel · CRVL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $646M | $719M | $795M | $896M | $959M |
| Revenue growth | 16.9% | 11.2% | 10.7% | 12.6% | 7.0% |
| Gross margin | 23.5% | 22.0% | 21.6% | 23.4% | 24.3% |
| Net income | $66.4M | $66.4M | $76.3M | $95.2M | $110M |
| Net margin | 10.3% | 9.2% | 9.6% | 10.6% | 11.5% |
| Diluted EPS | $1.22 | $1.26 | $1.47 | $1.83 | $2.14 |
| Cash | |||||
| Cash from operations | $67.2M | $82.3M | $99.2M | $127M | $156M |
| Capital expenditure | $29.8M | $26.3M | $29.2M | $35.8M | $45.4M |
| Free cash flow | $37.4M | $56.0M | $70.0M | $91.6M | $110M |
| FCF margin | 5.8% | 7.8% | 8.8% | 10.2% | 11.5% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $90.1M | $93.7M | $45.7M | $37.6M | $56.2M |
| Share count change | −0.2% | −3.0% | −1.4% | −0.1% | −0.7% |
| Debt and strength | |||||
| Cash and short-term investments | $97.5M | $71.3M | $106M | $171M | $233M |
| Shareholders' equity | $212M | $202M | $248M | $322M | $394M |
| Current ratio | 1.6x | 1.5x | 1.6x | 1.9x | 2.0x |
| Returns and quality | |||||
| Return on equity | 30.7% | 32.0% | 33.9% | 33.4% | 30.8% |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$21.2M
8 insiders
Of sales under plans
82%
$17.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
CorVel · CRVL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| CorVel CRVL | $4.3B | 7.0% | — | 11.5% | — | 37.6x | — |
| Sotera Health SHC | $5.3B | 5.7% | — | 12.8% | 6.7% | 32.3x | 7 |
| Tempus AI TEM | $13.4M | 83.4% | −19.9% | −18.8% | — | — | 5 |
| Addus HomeCare ADUS | $2.2B | 23.2% | 9.7% | 7.3% | 9.4% | 21.2x | 5 |
| Lifestance Health LFST | $5.1B | 13.9% | 1.7% | 7.7% | 1.2% | 100.5x | 7 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $84.59 a share, the company is worth $4.3B: 37.6 times its earnings of the last four quarters.
CorVel grew sales faster than 1 of its 4 similar companies. Its P/E is higher than 2 of 3.
Source: SEC EDGAR XBRL filings (CIK 0000874866). Data updated October 22, 2026. For information only — not investment advice. Check the original filings before relying on any figure.